Clearmind Medicine to consolidate shares 1-for-8 Oct. 5 on Nasdaq
CMND•Clearmind Medicine will execute a 1-for-8 reverse share split, with post-split trading on Nasdaq set to begin Oct. 5, 2026; shares outstanding are expected to fall to 507,404 from 4,059,227.
1. Reverse split details
Clearmind Medicine will execute a 1-for-8 reverse split of its common shares, with post-split trading on the Nasdaq Capital Market set to begin Monday, Oct. 5, 2026. Issued and outstanding shares are expected to decrease to 507,404 from 4,059,227, subject to fractional-share rounding; fractional shares will be rounded up to the nearest whole share. Options and warrants will be adjusted proportionately for share count and exercise price, and the new CUSIP will be 185053709.
